Koichi Takahashi is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 836 publications with 17,439 citations (h-index 70). By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Registry record last updated 2 Mar 2015.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202516 payments$18,091openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.5%BCL-2 Inhibitor39.4%Venclexta100%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor13.1%Tibsovo100%Part D<11 patientsAnti-infectives
47.5%Fluoroquinolone Antibacterial24.2%Levofloxacin100%Part D≥16 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor23.2%Valacyclovir100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Clonal competition between TP53 and PPM1D mutations in hematopoiesis
Baylor College of Medicine
FY2026$679,565R01CA237291 - Core A: Single Cell Profiling and Bioinformatics Core
Baylor College of Medicine
FY2026$379,592P01CA265748 - Core A: Single Cell Profiling and Bioinformatics Core
Baylor College of Medicine
FY2025$452,288P01CA265748
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”